Covance Clinical Research Unit
Madison, Wisconsin, 53704, United States
NCT Number: NCT04927793
A Phase 1, Open-label Study of the absorption, metabolism, and excretion of a single oral dose of [14C]EDP-938 in healthy male subjects.
Looking for future studies?
Notify Me18 year–55 year
Male
Interventional
Phase 1
Madison, Wisconsin, 53704, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
a. Subjects with a history of cholecystitis, cholelithiasis, and/or choledocholithiasis will also be excluded.
[14C]EDP-938
Time frame: Up to 11 days
Time frame: Up to 11 days
Time frame: Up to 11 days
Time frame: Up to 11 days
Time frame: Up to 11 days
Time frame: Up to 11 days
Time frame: Up to 11 days
Enanta Pharmaceuticals, Inc
Industry
A Phase I, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]EDP-938 Following a Single Oral Dose in Healthy Male Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06890416
Respiratory Syncytial Virus (RSV)
Birmingham, Alabama, United States
View Trial DetailsNCT06077149
Respiratory Syncytial Virus (RSV)
Rochester, New York, United States
View Trial DetailsNCT06473519
Infections, Mononegavirales Infections
South Miami, Florida, United States
View Trial DetailsNCT05842967
Respiratory Syncytial Virus (RSV)
Athens, Alabama, United States
View Trial Details